Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2003
08/07/2003WO2003063906A1 Drugs for treating inflammatory diseases
08/07/2003WO2003063900A1 Process for the preparation of a nutrient formulation
08/07/2003WO2003063893A2 Fgfr agonists
08/07/2003WO2003063876A2 Methods of treating patients suffering from movement disorders
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063870A1 A combination treatment for acute myocardial infarction
08/07/2003WO2003063869A1 Anti-viral compounds
08/07/2003WO2003063862A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003WO2003063860A1 Compositions for preventing human cancer and method of preventing human cancer
08/07/2003WO2003063848A1 Lutein/zeaxanthin for glare protection
08/07/2003WO2003063846A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
08/07/2003WO2003063845A1 Alpha 2 delta ligands to treat tinnitus
08/07/2003WO2003063844A2 Treatment of rheumatoid arthritis using imatinie
08/07/2003WO2003063840A2 Transmucosal delivery of proton pump inhibitors
08/07/2003WO2003063832A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003WO2003063828A1 Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
08/07/2003WO2003063826A2 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003WO2003063799A2 Compositions and methods for systemic inhibition of cartilage degradation
08/07/2003WO2003063797A2 Cycloalkyl inhibitors of potassium channel function
08/07/2003WO2003063796A2 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003WO2003063792A2 Compositions and methods related to tim-3, a th1-specific cell surface molecule
08/07/2003WO2003063789A2 L-carnitine for treatment of hearing loss
08/07/2003WO2003063782A2 Kappa-pviia-related conotoxins as organ protectants
08/07/2003WO2003063780A2 Therapeutic composition for treatment of cancer by arginine depletion
08/07/2003WO2003063779A2 Selective analgesic agents
08/07/2003WO2003063759A2 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
08/07/2003WO2003063576A2 Arylsulfonamidobenzylic compounds
08/07/2003WO2003063573A2 Method for treating diseases with omega interferon
08/07/2003WO2003046556A3 Globin biopolymer markers indicative of insulin resistance
08/07/2003WO2003045908A3 Method for controlling angiogenesis in animals
08/07/2003WO2003035002B1 Management of postoperative pain
08/07/2003WO2003030886A3 Allylamides useful in the treatment of alzheimer's disease
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2003024473A3 Retinoid receptor pan-antagonists for stimulating chondrogenesis
08/07/2003WO2003004034B1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
08/07/2003WO2002100415A3 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
08/07/2003WO2002059363A3 Method for detecting of prions in a sample
08/07/2003WO2002056873A3 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
08/07/2003WO2002018608A9 Methods for enhancing the efficacy of cancer therapy
08/07/2003WO2002004015A9 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2001092578A3 Reagents and methods for identifying and modulating expression of genes regulated by retinoids
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149128 Stabilized monomer adhesive compositions
08/07/2003US20030149111 For therapy of diabetes, hyperglycemia
08/07/2003US20030149109 (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof
08/07/2003US20030149101 Administering combination of a cholesterol lowering drug and an angiotensin converting enzyme inhibitor for therapy of atherosclerosis
08/07/2003US20030149090 Topically delivering an effective dose of a reactvie oxygen metabolites (ROM) production and release inhibitory compound in carrier to a subject suffering from ROM-mediated oxidative damage
08/07/2003US20030149088 Antiviral agent
08/07/2003US20030149076 Administering drug formulation comprising opioidergic agent and an insulin secretagogue for therapy of human suffering from one or more conditions included within Coronary Heart Disease Risk Factor Syndrome
08/07/2003US20030149070 Method of treating cardiovascular disease
08/07/2003US20030149066 Administering nalbuphine or a prodrug of nalbuphine, and an opioid antagonist selected from the group consisting of naloxone, naltrexone, nalmefene, pharmaceutically acceptable salts thereof or prodrugs
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149048 For therapy of hyperproliferative disorder in a mammal
08/07/2003US20030149013 Methods of treating bacterial infections in dogs and cats
08/07/2003US20030149012 Vision through photodynamic therapy of the eye
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149002 Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
08/07/2003US20030148991 Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders
08/07/2003US20030148990 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
08/07/2003US20030148987 Selective 11beta-HSD inhibitors and methods of use thereof
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148963 Use of etoposide at the manufacture of pharmaceutical formulations intended for the treatment of inflammations in mammals, including humans
08/07/2003US20030148949 Administering a trefoil peptide or biologically active fragment thereof to a skin lesion or region of the skin where a lesion is to be prevented; wound healing agents which can speed healing, reduce pain and delay/prevent lesions
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030148920 For inhibiting tumor-induced angiogenesis; antiischemic agents
08/07/2003US20030148458 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/07/2003US20030148451 Endothelial differntiation gene 6-like g protein coupled receptor
08/07/2003US20030148446 Acute neuronal induced calcium binding protein type 1 ligand
08/07/2003US20030148409 Genetically engineered monoclonal di/tri/tetra antibodies preferential tumor associated antigens for use in diagnosis and treatment of tumors
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148378 Phosphodiesterase 10
08/07/2003US20030148369 Novel uses of mammalian CCR8 receptors and related reagents
08/07/2003US20030148323 Analyzing nucleic acid and determining presence of mutant alleles encoding a protein with reduced activity/thermal stability; useful in diagnosing schizophrenia
08/07/2003US20030148274 Identification of neural defects associated with the nucleosomal assembly protein 112 gene
08/07/2003US20030148271 Given amino acid sequence; expression vectors, host cells; diagnosis, prevention and treatment of diseases associated with expression of the kallikrein
08/07/2003US20030148264 PDZ (PSD-95/Discs large/ZO-I) domains, (PSD-95 = post-synaptic density protein-95); PDZ proteins involved in assembling ion channels and other transmembrane receptors, at specialized subcellular sites such as tight junctions
08/07/2003US20030147996 Multiple antioxidant micronutrients
08/07/2003US20030147966 Nanoparticle delivery vehicle
08/07/2003US20030147957 An inner core formulated for controlled release comprising a mixture of a granulated admixture of a decarboxylase inhibitor and a surfactant, and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof;immediate release
08/07/2003US20030147945 Vehicles stably associated with non-antagonistic combinations of >/= 2 synergistic agents
08/07/2003US20030147893 Novel human transmembrane 4 superfamily protein
08/07/2003US20030147889 Administering type 1-interferon antibody, for inhibition of prevention of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis
08/07/2003US20030147887 B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
08/07/2003US20030147884 Administering a breast cancer patient (caused by human ErbB2 oncogene which codes a transmebrane glycoprotein receptor related to epidermal growth factor receptor, is overexpressed) an anti ErbB2 antibody and a drug
08/07/2003US20030147862 Administering a colony stimulating factor and/or a nucleic acids encoding the factor; treating a vascular tumor
08/07/2003US20030147856 Proteins
08/07/2003CA2813048A1 Composition for use in treating patients suffering from movement disorder
08/07/2003CA2514518A1 Process for the preparation of a nutrient formulation
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
08/07/2003CA2474821A1 Anti-viral compounds
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474689A1 Drugs ameliorating circadian rhythum disorder
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474616A1 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003CA2474590A1 Treatment of male sexual dysfunction
08/07/2003CA2474497A1 Compositions and methods related to tim-3, a th1-specific cell surface molecule
08/07/2003CA2474451A1 Cycloalkyl inhibitors of potassium channel function
1 ... 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 ... 1151